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In a cross-over RCT, portable NIV (pNIV) reduced dynamic hyperinflation (DH) 
compared to pursed lip breathing (PLB) during recovery from intermittent exercise in 
COPD, but not consistently in all subjects. In this post-hoc analysis, DH response was 
defined as a reduction ≥4.5% of predicted resting inspiratory capacity with pNIV 
compared to PLB. 
At exercise iso-time (where work completed was consistent between pNIV and PLB), 
8/24 patients were DH non-responders (DH: 240±40ml, p=0.001 greater using pNIV). 
16/24 were DH responders (DH: 220±50ml, p=0.001 lower using pNIV). Compared to 
DH responders, DH non-responders exhibited greater resting DH (RV/TLC: 65±4% 
versus 56±2%; p=0.028) and did not improve exercise tolerance (pNIV: 30.9±3.4 
versus PLB: 29.9±3.3 min; p=0.603). DH responders increased exercise tolerance 
(pNIV: 34.9±2.4 versus PLB: 27.1±2.3 min; p=0.001). Resting RV/TLC% was negatively 
associated with the magnitude of DH when using pNIV compared to PLB (r=-0.42; 
p=0.043). 
Patients with profound DH were less likely to improve exercise tolerance with pNIV. 










• The study provides proof of concept on how to select COPD patients likely to 
respond to portable NIV (pNIV) during intermittent exercise.  
• One third of patients (8/24) did not improve dynamic hyperinflation (DH non-
responders) with the application of pNIV compared to pursed lip breathing 
(PLB). 
• DH non-responders exhibited greater resting hyperinflation and tend towards 
worse spirometric measures compared to responders.  
• Exercise endurance was improved by using pNIV compared PLB in DH 
responders, but unchanged in non-responders. 
• Further studies in auto-adjusted ventilators are warranted in patients with 





In patients with COPD dynamic hyperinflation (DH) is associated with breathlessness 
and reduced exercise endurance. This affects functional independence, the ability to 
carry out activities of daily living, and quality of life (QOL) [Spruit, et al. 2013]. 
Pulmonary rehabilitation (PR) is a cornerstone of COPD treatment and improves 
exercise tolerance and QoL [Spruit, et al. 2013]. However, in patients with 
moderately severe and severe COPD presenting with exertional breathlessness, it is 
difficult to achieve the necessary intensity of exercise during PR to induce true 
physiological training effects [Maltais, et al. 1997].  
A variety of exercise training and ergogenic strategies aimed at reducing 
breathlessness have been described and evaluated within the literature, including 
intermittent exercise [Vogiatzis, et al. 2002], oxygen [O'Donnell, et al. 2001a] and 
heliox supplementation [Palange 2010] and Non-Invasive Ventilation (NIV) 
[Ambrosino and Cigni 2015,Ambrosino and Xie 2017]. Use of NIV has shown clinically 
meaningful benefits to exercise tolerance, DH and breathlessness, however there are 
limitations with the practical application of this approach during exercise in patients 
with COPD [Ambrosino and Cigni 2015,Ambrosino and Xie 2017]. Accordingly, 
investigating more effective ways to administer NIV in rehabilitation or exercise 
programs is justified [Vogiatzis, et al. 2019]. 
A novel hand-held, battery powered, portable NIV (pNIV) device (VitaBreath, Philips 
Respironics), provides bi-level positive airway pressure (BiPAP) and can be easily 
applied during recovery from exercise [Hardy and Jasko 2015]. Conventional NIV is 
used during exercise in COPD. However, according to the manufacturers’ 
specifications this particular hand held device was made to be used during daily 
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living activities in COPD to assist recovery of activity-related breathlessness [Hardy 
and Jasko 2015] thus, cannot be used during exercise. The VitaBreath device is no 
longer commercially available, but similar devices may come to market; the present 
study provides proof of concept on how pNIV can be applied intermittently during 
exercise in patients with COPD, and how to select patients most likely to respond. 
This in turn may also encourage development of more suitable devices. 
Our previous randomised crossover study showed that in COPD use of pNIV during 
recovery periods within intermittent exercise prolonged exercise endurance and 
reduced DH and breathlessness compared to pursed lip breathing (PLB)  [Vogiatzis, 
et al. 2019]. However, pNIV did not improve outcomes in all subjects; 8/24 patients 
failed to show a clinically significant improvement in DH (≥4.5% of predicted resting 
inspiratory capacity) using pNIV compared to PLB and were defined as ‘DH non-
responders’ [Vogiatzis, et al. 2019]. One technical limitation of this pNIV device is 
that the expiratory and inspiratory positive airway pressures (EPAP=8cmH2O and 
IPAP=18 cmH2O, respectively) are fixed, and therefore may have been sub-optimal in 
at least some of the patients.  
The aim of the present study was to compare the baseline characteristics, the 
respiratory and circulatory response during exercise and qualitative outcomes 
between DH responders and DH non-responders. We defined response in terms of 
DH as it is an objective physiological index that determines the clinical response. 
Whilst the primary outcome in the original RCT was exercise endurance, this is 
influenced by a variety of factors, some of which are subjective. Exercise endurance 




2.1 Study design 
This is a retrospective analysis conducted on data collected during a prior 
randomised open-label crossover trial comparing the use of pNIV to PLB during two 
exercise protocols; namely a high-intensity or a moderate-intensity intermittent 
exercise protocol [Vogiatzis, et al. 2019]. In accordance with the official ERS 
statement on the use of exercise testing in the evaluation of interventional efficacy 
[Puente-Maestu, et al. 2016] physiological variables recorded when using pNIV or 
the PLB were compared at exercise iso-time (where work complete was consistent 
between application of pNIV and PLB), therefore allowing comparisons to be made 
which were unaffected by the use of the different intermittent exercise protocols 
applied in the previous study [Vogiatzis, et al. 2019]. All investigations were carried 
out following ethical approval from the NHS Research Ethics Committee (REC: 
17/NE/0085) and following protocol submission for Clinical Trials Registration 
(NCT03068026). All studies were carried out in line with the Declaration of Helsinki. 
All participants provided written informed consent.  
2.2 Participants 
In the present analysis we included data from all 24 stable COPD patients who were 
included in the original study; inclusion and exclusion criteria have been described 





2.3 Baseline Assessment 
Prior to exercise testing, participants attended North Tyneside General Hospital for 
baseline assessment including spirometry, body plethysmography lung volume 
measurements, diffusion capacity and resting ECG evaluation [Vogiatzis, et al. 2019]. 
Following medical assessment, patients performed a ramp incremental 
cardiopulmonary exercise test to the limit of tolerance to establish presence of DH 
[Vogiatzis, et al. 2019,O'Donnell, et al. 2001b] and define peak work rate (WRpeak). 
All participants attended 6-8 practice exercise sessions with a qualified 
physiotherapist, where they were instructed of the correct PLB technique and use of 
the pNIV device prior their participation to the study [Vogiatzis, et al. 2019].   
2.4 Intermittent Exercise Protocols 
Participants were randomised to a high-intensity (HI; n=13) or a moderate-intensity 
(MOD, n=11) intermittent exercise protocol to the limit of tolerance using the pNIV 
or the PLB method in a balanced ordering sequence. HI consisted of 2-min cycling at 
80% WRpeak alternated with 2-min recovery periods (Figure 1a). MOD consisted of 
6-min cycling at 60% of WRpeak alternated with 2-min recovery periods (Figure 1b). 
In the first minute of each recovery period (either HI or MOD), participants were 
instructed to use either the pNIV device or the PLB technique in the predetermined 
balanced order. At rest and during the second minute of recovery patients were 
instructed to perform inspiratory capacity (IC) manoeuvres to assess DH [O'Donnell, 
et al. 2001b].  Pulmonary gas exchange, ventilatory variables and IC measurements 
were performed using a portable gas exchange analyser (K4b2, Cosmed, Shepperton, 
UK) at rest and throughout exercise testing. A portable cardio-impedance device 
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(Enduro, Physio flow, Manatec) was used to assess cardiac output throughout 
exercise testing. At predefined time points during exercise and at the limit of 
tolerance, patients were instructed to perform IC manoeuvres (Figure 1c). The 
Modified Borg Scale was used to assess the magnitude of dyspnoea and leg 
discomfort during the second minute of each recovery period [Borg 1982]. The 
exercise procedures and assessments have been explained in detail elsewhere 
[Vogiatzis, et al. 2019]. 
2.5 Use of pNIV in daily life 
Following completion of the exercise tests, all patients were provided with the 
VitaBreath device to use during daily life activities as they wished. Use of, and 
perceived benefit from, the VitaBreath device was assessed at 2 and 12 weeks post 
exercise testing. The survey included questions on symptom burden, ability to 
perform daily tasks and perceived benefit from the device. The components of the 
survey can be found elsewhere [Vogiatzis, et al. 2019]. 
2.6 Statistical analysis 
Data are presented as mean±SEM rather than SD because the comparisons of 
interest were in the mean values of various physiological variables under the two 
different breathing modalities (pNIV and PLB). As exercise time was different 
between the pNIV and PLB trials within the HI and MOD intermittent protocols, 
physiological measures were compared at the time point where the shortest trial 
(pNIV or PLB) was terminated (i.e., at exercise iso-time) [Puente-Maestu, et al. 2016]. 
DH response at exercise iso-time was calculated as the difference in IC between pNIV 
and PLB (i.e.: IC pNIV – IC PLB - a positive value indicating improvement with pNIV). 
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Patients who showed a clinically significant increase  in IC (≥4.5% of predicted resting 
IC [O'Donnell, et al. 2001b]) when using pNIV compared to the PLB technique at 
exercise iso-time were identified as ‘DH responders’. Patients showing a less than 
the clinically significant increase, or a decrease, in IC using pNIV compared to PLB 
were defined as ’DH non-responders’. Independent sample t-tests were carried out 
to compare variables between responders and non-responders for the baseline 
demographic and lung function characteristics. Two-way ANOVA with repeated 
measurements followed by least significant difference (LSD) post-hoc analysis was 
employed to compare physiological changes at exercise iso-time between pNIV and 
PLB techniques in both responders and non-responders. The results of the 
questionnaire between responders and non-responders were analysed by the 
Wilcoxon singed-rank test and presented as median (IQR). The level of significance 
for all analyses was set at p<0.05. 
3. Results 
The baseline characteristics of the patients are presented in table 1. Based on the DH 
data at exercise iso-time, 8 participants were identified as ‘DH non-responders’ to 
pNIV, whilst the remaining 16 participants were deemed as ‘DH responders’ to pNIV. 
Responders exhibited a tendency for greater FEV1, FVC, and resting IC compared to 
the non-responders. In addition, RV/TLC% was greater (p=0.028) in DH non-
responders compared to DH responders, indicating greater resting hyperinflation 
and mechanical restriction to tidal volume expansion (Table 1).  
In DH non-responders, exercise endurance time was not different when using the 
pNIV device (30.9±3.4 min) compared to PLB (29.9±3.3 min) (p=0.603). In DH 
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responders, exercise endurance time was significantly greater (p=0.001) with pNIV 
(34.9±2.4 min) compared to PLB (27.1±2.3 min) (Figures 2c & 2d & Table 2).   
At exercise iso-time in DH non-responders IC was 240±40 ml (p=0.001) lower with 
pNIV compared to PLB, whilst IC was 220±50 ml (p=0.001) greater in DH responders 
(Figure 2a & 2b & Table 2), (p=0.001) as expected. Across all 24 patients, the 
magnitude of change in exercise tolerance with pNIV compared to PLB was 
associated with the magnitude of change in DH (r=0.46, p=0.022) (Figure 3a). 
Furthermore, resting DH (inferred by RV/TLC %) was negatively associated with the 
magnitude of exercise-induced DH when using pNIV compared to PLB (r=-0.42, 
p=0.043) (Figure 3b).   
At exercise iso-time use of pNIV compared to PLB reduced breathlessness by a 
clinically meaningful margin (by 1.3±0.3 units, p=0.001) in DH responders [Puente-
Maestu, et al. 2016,O'Donnell, et al. 2018]. In DH non-responders the reduction in 
breathlessness, measured by Borg scale, with the use of pNIV compared to PLB (by 
0.6±0.5 units, p=0.118) was not clinically meaningful. In addition, use of pNIV 
compared to PLB reduced leg discomfort in both DH responders and non-responders 
(by 0.6±0.2 units, p=0.026 and by 0.8±0.3 units, p=0.034, respectively), albeit by non-
clinically meaningful margins [Jones, et al. 2014].  
In DH responders, application of pNIV compared to PLB reduced minute ventilation 
(by 1.0±0.8 L, p=0.224) due to lower breathing frequency (by 1±1 breaths.min-1 
p=0.216), whilst tidal volume was increased (by 0.1±0.02 L, p=0.018) (Table 2). In 
contrast, in DH non-responders pNIV compared to PLB increased minute ventilation 
(by 2.7±1.1 L, p=0.021) secondary to increased breathing frequency (by 2±1 
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breaths.min-1, p=0.046), whilst tidal volume was unaffected (Table 2). Thus, there 
was a significant difference in the breathing pattern of response between DH 
responders and DH non-responders with pNIV compared to PLB in minute ventilation 
(p=0.012), breathing frequency (p=0.026) and tidal volume (p=0.046).  
At exercise iso-time, the fraction of tidal volume to inspiratory capacity (VT/IC %) was 
increased in DH non-responders (by 6±2%, p=0.001) with the use of pNIV compared 
to PLB, whereas it was decreased (by 3±1%, p=0.010) in DH responders (Table 2). In 
addition, in DH non-responders there was a reduction in inspiratory time (by 
0.1±0.03 sec, p=0.017) and expiratory (by 0.2±0.1 sec, p=0.010) time, and total duty 
cycle (by 0.3±0.1 sec, p=0.008) with the use of pNIV compared to PLB (Table 2). 
There were no differences between pNIV and PLB in duty cycle in DH responders 
(Table 2). Thus, there was a significant difference in the pattern of response between 
DH responders and non-responders with pNIV compared to PLB in inspiratory time 
(p=0.004, expiratory time (p=0.004) and duty cycle (p=0.002). 
There were no differences in stroke volume and heart rate with pNIV compared to 
PLB in either of the groups (Table 2). However, in DH responders cardiac output was 
greater with pNIV compared to PLB (by 0.6±0.3 L.min-1, p=0.035) (Table 2), whereas 
cardiac output was not different between pNIV and PLB in DH non-responders.  
Compared to the pre-VitaBreath period, at 12 weeks DH responders were 
significantly less anxious about becoming breathless on a 10-point Likert Scale: 
(median (IQR) pre-VitaBreath=7.31 (5.25–9.75); 12 weeks=3.75 (2.00–5.75); 
(p=0.001) and 11 of 16 patients perceived a shorter time to recovery from 
breathlessness (p=0.004) (Table 3). In contrast, compared to the pre-VitaBreath 
12 
 
period, at 12 weeks in DH non-responders there was a trend to be less anxious about 
becoming breathless (pre-VitaBreath=6.88 (6.00–8.00); 12 weeks=4.75 (2.25–7.25); 
(p=0.127)  and 5 of 8 patients perceived a shorter time to recovery from 
breathlessness (p=0.034) (Table 3). 
4. Discussion 
The main finding of this analysis was that only DH responders showed an 
improvement in exercise tolerance with pNIV compared to PLB. DH non-responders 
showed similar exercise tolerance with pNIV and PLB. Compared to DH responders, 
DH non-responders had greater resting DH, thus greater mechanical restriction to 
tidal volume expansion during exercise, and tended towards more severe airflow 
obstruction. The application of pNIV worsened ventilatory responses in DH non-
responders, who adopted a more tachypnoeic breathing pattern, but improved the 
ventilatory response in DH responders.   
Our findings within DH responders are supported by previous research into different 
NIV modes as an adjunct to exercise training, where increases in exercise tolerance 
similar to the present study are reported [Ambrosino and Cigni 2015,Ambrosino and 
Xie 2017]. Lack of improvement in exercise endurance time in DH non-responders 
may be attributed to the failure of pNIV to reduce DH and thus relieve symptoms of 
breathlessness. There is strong evidence that a reduction in the mechanical 
restriction to tidal volume expansion is closely related to a reduction in symptoms of 
exertional breathlessness [O'Donnell, et al. 2018,Laviolette and Laveneziana 
2018,Neder, et al. 2019]. Additionally, a study by Fröhlich and colleagues reported 
that exercise capacity was significantly lower in patients with greater baseline 
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RV/TLV compared to patients with lower RV/TLC [Fröhlich, et al. 2019]. These 
findings are further supported by the study of Neder and colleagues that reported 
that in patients with COPD, the lower the end-expiratory lung volume over the total 
lung capacity ratio is (and thus, the RV/TLC) the greater the exercise tolerance 
[Neder, et al. 2019]. Therefore, the potential mechanism explaining the lack of 
improvement in exercise tolerance in DH non-responders when using pNIV 
compared to PLB is probably the failure to alleviate such mechanical constraints 
[O'Donnell, et al. 2018,Laviolette and Laveneziana 2018,Neder, et al. 2019], and 
subsequently to reduce symptoms of breathlessness by a clinically meaningful 
amount (>1.0 on a Borg 1-10 scale) as observed with the DH responders [Puente-
Maestu, et al. 2016].   
DH is an important factor limiting exercise tolerance in patients with COPD 
[O'Donnell, et al. 2001b,O'Donnell, et al. 2018,Laviolette and Laveneziana 2018].  
Compared to DH responders, DH non-responders tended to have a lower FEV1, 
which is associated with increased lung volumes and greater lung hyperinflation at 
rest [O'Donnell, et al. 2001b]. These findings are consistent with advanced COPD 
with emphysema [Bailey 2012].. Although both groups exhibited a reduction in Borg 
scale breathlessness when using pNIV, only DH responders achieved a clinically 
meaningful reduction (>1.0 units) [Puente-Maestu, et al. 2016]. In COPD, DH causes 
inspiratory muscle shortening and tidal volume constraints, effecting ventilatory and 
central motor output [Laviolette and Laveneziana 2018,O'Donnell and Laveneziana 
2007] and thus increasing work of breathing and consequent breathlessness. 
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The reduction in the magnitude of DH when using pNIV compared to PLB in DH 
responders is most likely associated with the greater ability to expand tidal volume 
during exercise, resulting in improved ventilatory coupling and subsequent reduction 
in breathlessness [Laviolette and Laveneziana 2018,O'Donnell and Laveneziana 
2007]. Use of pNIV in DH responders was associated with an increase tidal volume 
with lower breathing frequency, increasing the duty cycle. These findings are in 
accordance with the existing literature showing that even relative small changes in 
tidal volume and breathing frequency are associated with reduced breathlessness 
during constant load exercise at 75% of WRpeak following bronchodilator therapy 
[Peters, et al. 2006]. In contrast, the more tachypnoeic breathing pattern adopted by 
DH non-responders resulted in less expiratory time and thus increased air trapping 
and exacerbated breathlessness [O'Donnell, et al. 2018,Laviolette and Laveneziana 
2018,Neder, et al. 2019]. The increased fraction of tidal volume to inspiratory 
capacity (VT/IC %) in DH non-responders demonstrates they were more likely to 
reach the point during exercise where they were unable to further increase tidal 
volume when using pNIV compared to PLB (Table 2) [O'Donnell, et al. 2001b]. It is 
possible that in some subjects the fixed EPAP was insufficient to overcome flow 
limitation, thus failed to facilitate expiration, or that excessive pressures directly 
worsening DH. Use of self-adjusting EPAP tailored to the individual patient may lead 
to better outcomes. 
A recent study by Souza and colleagues [Souza, et al. 2019] reported that application 
of bi-level Positive Airway Pressure -BiPAP (IPAP: 15 cmH2O, EPAP: 5 cmH2O) in 
moderate COPD reduced operational lung volumes and breathlessness, increasing 
exercise tolerance at different levels of exercise. However, in contrast to the present 
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study, BiPAP was applied throughout exercise and IPAP and EPAP pressures were 
tailored to a level that was comfortable to the individual patient [Souza, et al. 2019]. 
The VitaBreath device delivers fixed pressures of 18 cmH2O inspiratory pressure and 
8 cmH2O expiratory pressure. For NIV to be beneficial in COPD patients, the external 
positive end-expiratory pressure (PEEPe) provided by the ventilator must match the 
patients intrinsic PEEP (PEEPi) [Mora Carpio and Mora 2019]. The fixed pressures of 
VitaBreath are in contrast to other commonly used, adjustable, NIV methods, and it 
is likely that the pressures provided by the pNIV device were excessive for the DH 
non-responders [Cain, et al. 2019]. A study by Nava and colleagues reported that 
application of PEEPe greater that PEEPi significantly increased end-expiratory lung 
volumes [Nava, et al. 1993]. In the present study, 8 patients exhibited greater DH, 
whilst 16 patients experienced less DH with pNIV compared to PLB. Although PEEPi 
was not assessed in this study, the level of PEEPe (8 cmH2O) provided by the 
VitaBreath device was suboptimal compared to the intrinsic PEEPi levels of 
2.5cmH2O reported in the literature for patients with similar severity of COPD to 
those in the present study, most likely worsened DH in our DH non-responders 
[Nava, et al. 1993]. Furthermore, when intrinsic and extrinsic PEEP matching is 
suboptimal, there is increased risk of developing patient-ventilator asynchrony 
[Milesi, et al. 2017], resulting in increased work of breathing, poor alveolar 
ventilation and insufficient gas exchange [Tams, et al. 2013]. This supports our view 
that the ability to match PEEPe to the individual patient’s needs in future pNIV 
devices should improve synchrony and lead to a greater reduction in exercise 
induced DH, thus improving exercise tolerance and breathlessness. 
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A potential factor facilitating DH responders to increase their exercise tolerance is 
the greater BMI compared to DH non-responders. A review by O’ Donnell et al., 
[O'Donnell, et al. 2014] suggested that increased BMI is associated with increased 
airway resistance and work of breathing in patients with COPD at rest. Moreover, 
the same study presents lower DH in obese COPD patients compared to normal 
weight patients with the same disease severity during an incremental 
cardiopulmonary exercise test [O'Donnell, et al. 2014]. The authors concluded that 
the respiratory muscles in obese patients with COPD might have a mechanical 
advantage compared to normal weight patients with the same disease severity, due 
to the greater absolute IC and the lower operating lung volumes during exercise 
[O'Donnell, et al. 2014]. This allows obese patients with COPD to perform physical 
tasks requiring increased ventilation without increased breathlessness [O'Donnell, et 
al. 2014]. Given the high levels of positive inspiratory and expiratory pressures 
provided by the VitaBreath device, it is likely that PEEPi and PEEPe were closer 
matched in patients with high BMI, thereby enchasing the mechanical advantages 
previously reported during exercise [O'Donnell, et al. 2014]. 
Only 63% of non-responders reported faster recovery from breathlessness after 12 
weeks of using the VitaBreath device compared to 75% of responders.  Furthermore, 
only patients in the DH responders group reported a significant reduction in anxiety 
related to breathlessness during activities of daily life.  
4.1 Study limitations 
This is a post hoc analysis and response was defined in terms of DH and not the primary 
outcome (exercise endurance time) of the original study. Inspiratory and expiratory 
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positive airway pressures provided by the pNIV device were fixed, therefore 
adjustment of the aforementioned pressures was not possible. This is distinct to 
other studies applying NIV in COPD patients given that the level of provided pressure 
is individualised to maximise the benefit of use. This represents a very important 
disadvantage of the VitaBreath device, which clearly mitigated the beneficial impact 
it had on some patients. 
4.2 Clinical implications 
The findings of the present study suggest that, although pNIV presents with 
promising results and favourable practical benefits, it is not effective in improving 
DH in all COPD patients. This may be because the fixed pressures were suboptimal in 
some of the patients. Further studies in auto-adjusted ventilators are warranted in 
this population. However, use of self-adjusting EPAP during physical effort has not 
been demonstrated and this seems complicated due to the actual device algorithm.  
Considering the variation in response we have reported, it is important that clinicians 
assess the response to pNIV on an individual basis in order to verify whether using a 
portable NIV device during rehabilitation or at home makes the patient feeling 
better or worse. Clinicians may administer a similar questionnaire to patients as the 
one used in our original study [Vogiatzis, et al. 2019] to evaluate perception of 
breathlessness when using a pNIV device on an individual basis. The findings of the 
present study provide evidence that patients who cannot tolerate continuous NIV 
methods during exercise, may use the NIV apparatus in recovery from exercise when 
an intermittent mode of exercise is undertaken. This approach will facilitate the 
majority of patients to recover from breathlessness faster, thereby increasing the 
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Application of pNIV during the recovery from intermittent exercise improves exercise 
tolerance and breathlessness in the majority of COPD patients. However, this is not 
the case in patients with profound resting dynamic hyperinflation and ventilatory 
constraints during exercise.  
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Gender (M/F) 4/4 6/10  
Age (years) 67±3 67±2 0.934 
BMI 24.4±3.1 27.2±1.5 0.363 
FEV
1
 (litres) 0.96±0.20 1.23±0.16 0.297 
FEV
1
 (% predicted) 40±8 49±4 0.292 
FVC (litres) 2.57±0.35 2.78±0.20 0.594 
FVC (% predicted) 86±7 91±5 0.590 
FEV
1
/FVC 37±5 43±3 0.298 
FRC (% predicted) 188±14 166±12 0.288 
RV (% predicted) 218±20 198±17 0.470 
TLC (% predicted) 135±6 128±7 0.564 
IC (% predicted) 70±7 84±6 0.164 
IC/TLC (%) 24±3 30±2 0.047 
RV/TLC (%) 65±4 56±2 0.028 
DLco (litres) 2.60±1.01 3.17±0.44 0.556 
DLco (% predicted) 33±11 40±5 0.494 
WRpeak (% predicted) 41±8 48±6 0.471 
VO2peak (%predicted) 59±7 61±4 0.722 
 
M, male; F, female; BMI, body mass index; FEV1, forced expiratory 
volume in the first second; FVC, forced vital capacity; FRC, functional 
residual capacity; RV, residual volume; TLC, total lung capacity; IC, 
inspiratory capacity; DLco, transfer factor of the lung for carbon 
monoxide; WRpeak, peak work rate; VO2peak, peak oxygen uptake; 





Table 2. Ventilatory and circulatory responses with the use of PLB or pNIV at exercise 
iso-time in DH non-responders and DH responders 
 DH Non-Responders DH Responders 
 PLB pNIV p PLB pNIV p 
Endurance time 
(min) 




28.0±5.8 30.7±5.6 0.021 37.8±4.1 36.8±4.0# 0.224 
Tidal volume 
(litres) 
1.0±0.2 1.0±0.2 0.482 1.2±0.1 1.3±0.1# 0.018 
IC (litres) 2.14±0.24 1.90±0.25 0.001 2.19±0.17 2.41±0.18# 0.001 
VT/IC (%) 47±3 53±3 0.001 56±2 53±2 0.010 




0.8±0.1 0.7±0.1 0.017 0.8±0.1 0.8±0.1# 0.059 
Expiratory time 
(sec) 
1.5±0.1 1.3±0.1 0.010 1.3±0.1 1.4±0.1# 0.116 
Duty cycle (sec) 2.3±0.1 2.0±0.1 0.008 2.1±0.1 2.2±0.1# 0.071 
Stroke volume 
(ml) 
88±7 88±6 0.971 95±5 98±5 0.122 
Heart rate 
(beats.min-1) 
111±6 114±6 0.223 109±4 108±4 0.913 
Cardiac output 
(L.min-1) 
9.5±0.9 9.9±0.8 0.335 10.3±0.6 10.9±0.6 0.035 
PLB, pursed lip breathing; pNIV, portable non-invasive ventilation; VT, tidal volume; 
IC, inspiratory capacity; bf, breathing frequency #: significant differences (p<0.05) in 
the pattern of response between the two groups; values presented as mean ± 
standard error of the mean (SEM). 
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Table 3. Effect of the use of VitaBreath device on anxiety and recovery from breathlessness 
in DH responders and DH non-responders 
 
 
DH Non-Responders DH Responders 
















1 = Not at all 
anxious 
6 improvements 15 improvements 
10 = Very 
anxious 
1 worse   
  1 ties 1 ties 
How long did 
it take you to 
recover from 
SOB? 
    0.034 *     0.004 * 
<1 min 0 (0%) 2 (25%) 5 improvements 1 (6.3%) 4 (25%) 11 improvements 
2–3 min 3 (37.5%) 3 (37.5%)   3 (18.8%) 6 (37.5%) 1 worse 
4–5 min 1 (12.5%) 1 (12.5%) 3 ties 2 (12.5%) 3 (18.8%) 4 ties 
5–7 min 2 (25%) 0 (0%)   2 (12.5%) 1 (6.3%)   
7–10 min 0 (0%) 0 (0%)   6 (37.5%) 2 (12.5%)   
More than 10 
min 
2 (25%) 2 (25%)   2 (12.5%) 0 (0%)   
 










Figure 1. Exercise protocols: (a) High-intensity 2-min exercise / 2-min rest intermittent 
protocol and (b) moderate-intensity 6-min exercise / 2-min rest intermittent protocol; (c) 
conceptual representation of the exercise iso-time point, where work completed was 
consistent between the application of NIV and PLB in both protocols, thereby allowing 
comparisons to be made that were unaffected by the HI or MOD exercise protocols. Dotted 
line denotes exercise iso-time where comparisons were made. IC denotes inspiratory 









Figure 2. Individual differences in inspiratory capacity (IC) at exercise iso-time (a & b) and in 
endurance time (c & d) between pNIV and PLB, in DH non-responders (left panel) and DH 
responders (right panel). Thick lines represent mean±SEM. Asterisks denote significant 






Figure 3. a) Association between differences in endurance time and in inspiratory capacity 
(IC) between pNIV and PLB application at exercise iso-time (r=0.46, p=0.022) and b) 
association between differences in IC when using pNIV compared to PLB at exercise iso-time 
with baseline residual volume as a fraction of total lung capacity ratio (RV/TLC) (r=-0.42, 
p=0.043). Open symbols denote DH non-responders and closed symbols DH responders. 
 
 
